Biomedical subjects

M Magub

Publications and source records attributed to M Magub.

4 recordsLinked to original sources

PubMed1984

[Psoriatic rheumatism].

Approximately 5% of patients with psoriasis develop chronic inflammatory joint disease which is clearly differentiated from rheumatoid arthritis by several features; absence of prevalence in females, elective involvement of distal joints of hands and feet, negative serologic tests, usually less severe outcome and absence of systemic manifestations. Conversely, psoriatic rheumatism resembles ankylosing spondylitis inasmuch as mainly sacroiliac but also vertebral involvement is common, with, in some instances, development of a typical pelvispondylitis. Thus, psoriatic rheumatism belongs to the group of seronegative spondylarthropathies. The genetic background of psoriatic rheumatism, with the exception of predominantly axial forms which are related to HLA B27, is very similar to that of isolated psoriasis, typified in particular by the frequency of HAL B17, B13 and B38. The immunologic disorders described in psoriasis and, more recently, in psoriatic rheumatism suggest that an immunologic dysfunction probably plays a significant part in the genesis of both conditions; however, the reasons why only a small proportion of patients with psoriasis develop joint disease remain obscure.

Chronic Disease↗

PubMed1983

[Articular manifestations of Yersinia infections. Apropos of 4 personal cases. Review of the literature].

The reactive arthritis due to Yersinia enterocolitica (YEC) have been know for a little more than ten years. A great many cases have been reported, especially by Scandinavian authors. In contrast, few cases have been reported in the course of Yersinia pseudotuberculosis infections (YPT). Analysis of 36 cases in the literature shows that although they are rare, the YPT reactive arthritis do exist and are not fundamentally different from those due to YEC. A few minor differences in their clinical signs have been demonstrated: the higher incidence of erythema nodosa and the lower incidence of cardiac involvement in the cases due to YPT. In both forms, there is a characteristic genetic predisposition, marked by the high incidence of the antigen HLB B27 (50 to 80 p. cent), which explains their strict relationship with diseases of the rheumatic pelvispondylitis group.

Adolescent↗

PubMed1982

Serum beta-2-microglobulin in multiple myeloma: relation to presenting features and clinical status.

Serum beta-2-microglobulin (B2m) levels were measured in 78 patients with multiple myeloma (MM) and were compared with values for normal individuals and patients with benign monoclonal gammopathies (BMG). Serum B2m levels and values corrected for renal function were significantly higher in patients with MM at time of diagnosis than in normal individuals (P less than 0.001) and were highly correlated with the total body burden of myeloma cells as derived from the staging system of Durie and Salmon. However there were no significant differences between values for BMG and low-mass MM. For patients evaluated following induction chemotherapy, there was also a clear correlation between serum B2m levels and the magnitude of tumor regression or progression (P less than 0.05). During the plateau-phase, serum B2m levels remained very stable and highly correlated with the residual tumor mass (P less than 0.001). It was concluded that (1) B2m was not a reliable marker to distinguish between BMG and low-mass MM and (2) B2m was a valuable marker for assessing initial tumor mass of patients with MM and response to chemotherapy (especially the plateau-phase), above all in patients with urine or low-serum monoclonal component levels.

Antineoplastic Agents↗

PubMed1981

[Serum beta-2-microglobulin in multiple myeloma. Practical value].

The concentration of serum, beta-2-microglobulin (S beta 2m) and the ratio measured S 2m/theoretical S beta 2m M/TH were evaluated in 69 patients with multiple myeloma (MM) and compared with healthy subjects and with patients with a benign monoclonal gammapathy. The concentration of S beta 2m and the ratio S beta 2m M/TH are higher in multiple myeloma than in controls and are strongly correlated with the plasma cell mass On the other hand, no difference was noted concerning the S beta 2m and the ration S beta 2m M/TH between benign monoclonal gammopathy and multiple myeloma at stage I of Durie and Salmon. Under chemotherapy, the variations in concentrations of S beta 2m and of the ratio S beta 2m M/TH are strongly correlated with those of the tumour mass. Beta 2m is not very useful for the differential diagnosis between benign monoclonal gammapathy and multiple myeloma. Beta 2m is very useful in the prognosis of MM, permitting one to assess accurately the tumour mass and the response to treatment, particularly in cases of deficiency of the usual markers.

Beta-Globulins↗